Catalyst Wire Dossier Catalyst Wire Dossier

Necitumumab

necitumumab · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

12 regulatory and trial events tracked for Necitumumab, covering 2016-05-05 to 2026-03-10. Get the full timeline:

Most recent: Clinical Trial Update: Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer [Phase 1, Phase 2]

See pricing